An Open-label, Single-Sequence, 2-Treatment Period Study to Investigate the Effects of Cytochrome P450 3A4 Inhibition by Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants
Latest Information Update: 21 Apr 2022
At a glance
- Drugs Afimetoran (Primary) ; Itraconazole
- Indications Autoimmune disorders; Cutaneous lupus erythematosus; Systemic lupus erythematosus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 18 Mar 2022 Results assessing impact of itraconazole on PK of BMS-986256, presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 25 Oct 2019 Status changed from recruiting to completed.
- 12 Aug 2019 Planned number of patients changed from 24 to 45.